Determination of SARS-CoV-2 Antispike Immunoglobulin G Level after First Dose of Oxford-AstraZeneca Vaccine among Healthcare Workers in Khartoum State

Abstract

This descriptive study was done during the period from 3 to 11 June 2021 to determine the level of SARS-CoV-2 antispike IgG among Healthcare workers after the first dose of Oxford-AstraZenka vaccine in Khartoum state. A total of 40 blood samples were randomly collected. Four ml of blood samples have been collected from each participant and placed in a plain container to obtain serum samples after centrifugation for SARS-CoV-2 anti-spike IgG. The serum samples were analyzed using Chorus TRIO analyzer based of (Enzyme-Linked- Immuno Sorbent-Assay) technique. Our results showed that 22 (55%) of the participants were females whereas 18 (45%) were males. Most of the participants 28 (70%) aged 25-30 years old and most of them 35 (87.5%) reside in Omdurman city. Several clinical symptoms have been exhibited by participants after vaccination, ranging from arm pain at the side of the injection, headache, fever, fatigue, and GIT disturbances. With the exception of one participant, none of them have a history of previous COVID19 infection. Our results showed that 30 (75.0%) of participants were reactive (positive SARS-CoV-2 IgG) after the first dose of Oxford-AstraZenka and SARS-CoV anti-spike IgG antibody titers ranged from 1.2-2.7 S/CO and a few of participants 9 (22.5%) showed doubtful result and only one participant 2.5% have shown negative result for anti-spike IgG antibody. The mean antibody titer for male 1.47 was significantly lower than female 1.49 with P-value 0.18. Our results confirm earlier studies on Oxford-AstraZenka vaccine efficacy